Key Findings
Roivant Sciences has announced the settlement of its long-standing litigation with Moderna, receiving a total settlement amount of $771.6 million. This landmark settlement includes a comprehensive cross-licensing agreement where Moderna will grant Genevant Sciences and Arbutus Biopharma non-exclusive licenses for Lipid Nanoparticle (LNP) and GalNAc technologies across all future applications, excluding hepatitis B virus-related and certain specified fields. This settlement clearly demonstrates the value of LNP technology and the significant impact of intellectual property rights in the biopharmaceutical industry.
Technical and Clinical Details
Lipid Nanoparticles (LNPs) are crucial for the delivery of messenger RNA (mRNA) vaccines and gene therapies, forming the foundation of Moderna’s successful COVID-19 vaccine. GalNAc (N-acetylgalactosamine) technology enables the targeting of nucleic acids to liver cells, finding applications in the development of treatments for specific liver diseases. This cross-licensing agreement will allow Genevant and Arbutus non-exclusive access to LNP and GalNAc technologies for a wide range of future therapeutic developments (excluding hepatitis B virus and certain other fields). The settlement funds will be allocated 80% to Genevant and 20% to Arbutus, after deducting their respective litigation costs, based on Genevant’s 83% and Arbutus’s 16% ownership of Genevant Sciences Ltd. (GSL) outstanding common stock.
Background and Industry Context
Intellectual property disputes surrounding LNP technology intensified with the rise of mRNA medicines, highlighting the critical importance of their technological foundation. The litigation between Moderna and Arbutus/Genevant concerned early contributions to the development of LNP delivery systems and subsequent commercial successes. With the settlement, both companies are freed from legal conflicts, allowing them to focus on their respective business strategies. This resolution solidifies LNP technology’s continued central role in the medical field, particularly in nucleic acid medicines and gene therapy, and underscores that technology licensing and partnerships are essential for driving innovation within the complex landscape of intellectual property rights.
Strategic Significance and Outlook
The substantial settlement payment from Moderna to Roivant Sciences and the cross-licensing agreement for LNP/GalNAc technologies will significantly influence strategic moves in the biopharmaceutical industry, especially in gene therapy and nucleic acid medicine sectors. Genevant and Arbutus gain the opportunity to invest the settlement funds and leverage the licensed technologies to further strengthen their pipeline development and platform technologies. For Moderna, this settlement provides a clear path to focus on future innovation and broader applications of LNP technology. This development is expected to facilitate the standardization and access to LNP technology, accelerating the development of next-generation gene and RNA therapies. In the future, new LNP-based modalities are anticipated to find clinical applications across more diverse disease areas, significantly expanding treatment options for patients.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments